Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Are Carbonic Anhydrases Suitable Targets to Fight Protozoan Parasitic Diseases?

Author(s): Katia D'Ambrosio*, Claudiu T. Supuran and Giuseppina De Simone*

Volume 25, Issue 39, 2018

Page: [5266 - 5278] Pages: 13

DOI: 10.2174/0929867325666180326160121

Price: $65

Abstract

Protozoans belonging to Plasmodium, Leishmania and Trypanosoma genera provoke widespread parasitic diseases with few treatment options and many of the clinically used drugs experiencing an extensive drug resistance phenomenon. In the last several years, the metalloenzyme Carbonic Anhydrase (CA, EC 4.2.1.1) was cloned and characterized in the genome of these protozoa, with the aim to search for a new drug target for fighting malaria, leishmaniasis and Chagas disease. P. falciparum encodes for a CA (PfCA) belonging to a novel genetic family, the η-CA class, L. donovani chagasi for a β-CA (LdcCA), whereas T. cruzi genome contains an α-CA (TcCA). These three enzymes were characterized in detail and a number of in vitro potent and selective inhibitors belonging to the sulfonamide, thiol, dithiocarbamate and hydroxamate classes were discovered. Some of these inhibitors were also effective in cell cultures and animal models of protozoan infections, making them of considerable interest for the development of new antiprotozoan drugs with a novel mechanism of action.

Keywords: Carbonic anhydrases, parasitic diseases, malaria, leishmaniasis, Chagas disease, protozoa.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy